Kummar S, Berlin J, Mascarenhas L, van Tilburg CM, Geoerger B, Lassen UN, Schilder RJ, Turpin B, Nanda S, Keating K, Childs BH, Chirila C, Laetsch TW, Hyman DM, Drilon A, Hong DS. Quality of life in adult and pediatric patients with tropomyosin receptor kinase fusion cancer receiving larotrectinib. Curr Probl Cancer. 2021 Dec;45(6):100734. doi: 10.1016/j.currproblcancer.2021.100734
Lennon RP, Sakya SM, Miller EL, Snyder B, Yaman T, Zgierska AE, Ruffin 4th MT, Van Scoy LJ. Public intent to comply with COVID-19 public health recommendations. Health Lit Res Pract. 2020 Aug 6;4(3):e161-5. doi: 10.3928/24748307-20200708-01
Block, Jr. R, Berg A, Lennon RP, Miller EL, Nunez-Smith M. African American adherence to COVID-19 public health recommendations. Health Lit Res Pract. 2020 Aug 6;4(3):e166-70. doi: 10.3928/24748307-20200707-01
Henk HJ, Kaye JA, Rothman KJ, Becker LK, Legg JC, Li X. Variation by age in neutropenic complications among patients with cancer receiving chemotherapy. Community Oncol. 2013 Jan 1;10(1):16-26.
Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Community Oncol. 2009 Nov 1;6(11):494-502.
Buchanan A, Sugg Skinner C, Calingaert B, Schildkraut J, King R, Marcom K. Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. Community Oncol. 2009;6(2):70-7.
Wenham RM, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, Lancaster JM, Schildkraut J, Marks J, BerchucK A. Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer. J Soc Gynecol Investig. 2003 Sep 1;10(6):381-7.